Israel’s Andromeda Biotech has reported success in the Phase III clinical trial of its Diapep277 drug for the treatment of Type 1 (juvenile) diabetes. The trial met its primary and secondary endpoints, and was found to be effective and safe.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000699926